Tillman Gerngross, Adagio CEO

Ada­gio raised $750M+ for an an­ti­body against fu­ture vari­ants. It failed against Omi­cron

Since the pan­dem­ic be­gan in the spring of 2020, Till­man Gern­gross has raised more than half a bil­lion dol­lars for his start­up Ada­gio and their promise to de­vel­op a so-called broad­ly neu­tral­iz­ing coro­n­avirus an­ti­body that could snare any vari­ant.

When Omi­cron broke out over Thanks­giv­ing, bring­ing a strain that threat­ened to evade wide­ly-used an­ti­body treat­ments from Eli Lil­ly and Re­gen­eron, Ada­gio’s $AD­GI soared 34% as Gern­gross’ pre­dic­tions ap­peared to come true. Ear­ly com­pu­ta­tion­al analy­ses sug­gest­ed Ada­gio’s an­ti­body, ADG20, cur­rent­ly in piv­otal tri­als, should re­tain full ef­fi­ca­cy against the vari­ant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.